Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer

Next Previous
X
Search
Trial Profile

NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGR-TNF (Primary) ; Doxorubicin
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms NGR012
  • Sponsors AGC Biologics

    • Most Recent Events

    • 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
    • 04 Jun 2012 Three-year follow-up data were presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a MolMed media release.
    • 17 May 2012 Results will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a MolMed media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top